Invitae Corporation (NVTA)
(Delayed Data from NYSE)
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$24.76 USD
+0.60 (2.48%)
Updated May 3, 2019 04:02 PM ET
After-Market: $24.77 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed the most recent trading day at $32.81, moving -1.97% from the previous trading session.
Here's Why Invitae (NVTA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Invitae (NVTA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Moving Average Crossover Alert: Invitae
by Zacks Equity Research
Invitae Corporation (NVTA) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Invitae (NVTA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NVTA) Outperforming Other Medical Stocks This Year?
Invitae (NVTA) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Invitae (NVTA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Is Invitae (NVTA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NVTA) Outperforming Other Medical Stocks This Year?
Is Invitae (NVTA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (NVTA) Outperforming Other Medical Stocks This Year?
Invitae (NVTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of 4.76% and 3.45%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
Will Invitae Corporation Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Invitae Corporation
Earnings Preview: Invitae (NVTA) Q1 Earnings Expected to Decline
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Invitae (NVTA) closed at $14.19, marking a +0.71% move from the previous day.
Invitae (NVTA) Stock Moves -0.59%: What You Should Know
by Zacks Equity Research
Invitae (NVTA) closed at $10.09 in the latest trading session, marking a -0.59% move from the prior day.
Is the Options Market Predicting a Spike in Invitae (NVTA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Where the Bulls Roam: TSLA, ILMN, SQ, NVTA, TTD
by Kevin Cook
Do you know which investment whales were buying and selling your favorite stocks before the big rally to new highs?
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider who delivered 181% revenue growth and 18,500 tests to patients and labs partners with Amgen
Implied Volatility Surging for Invitae (NVTA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Bull of the Day: Guardant Health (GH)
by Kevin Cook
Cancer diagnostics provider just delivered 181% revenue growth and 18,500 tests to patients and labs
Invitae (NVTA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -32.69% and 2.75%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?
by Zacks Equity Research
Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.
Earnings Preview: Invitae (NVTA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Invitae (NVTA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Invitae (NVTA) closed at $21.68, marking a -1% move from the previous day.
Invitae (NVTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -8.33% and 5.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Invitae (NVTA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Invitae (NVTA) stock based on the movements in the options market lately.
Analysts Estimate Invitae (NVTA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.